{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:47Z","timestamp":1791919607485,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100422","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T17:57:40Z","timestamp":1646675860000},"page":"100422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma"],"prefix":"10.1016","volume":"7","author":[{"given":"M.","family":"Lagan\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zamparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.D.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gianoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Turla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Terzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.M.","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2022.100422_bib1","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100422_bib2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.esmoop.2022.100422_bib3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.esmoop.2022.100422_bib4","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100422_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.esmoop.2022.100422_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100422_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40618-013-0049-2","article-title":"Management of adrenal cancer: a 2013 update","volume":"37","author":"Terzolo","year":"2014","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100422_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience","volume":"12","author":"Lagan\u00e0","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2022.100422_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.esmoop.2022.100422_bib10","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.esmoop.2022.100422_bib11","doi-asserted-by":"crossref","first-page":"624102","DOI":"10.3389\/fendo.2021.624102","article-title":"Clinical prognostic factors in patients with metastatic adrenocortical carcinoma treated with second line gemcitabine plus capecitabine chemotherapy","volume":"12","author":"Grisanti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.esmoop.2022.100422_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coemr.2019.07.007","article-title":"Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures","volume":"8","author":"Grisanti","year":"2019","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100422_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100422_bib14","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1530\/EC-18-0398","article-title":"Immunotherapy failure in adrenocortical cancer: where next?","volume":"7","author":"Cosentini","year":"2018","journal-title":"Endocr Connect"},{"issue":"36","key":"10.1016\/j.esmoop.2022.100422_bib15","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2217\/fon-2020-0686","article-title":"The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma","volume":"16","author":"Grisanti","year":"2020","journal-title":"Future Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2022.100422_bib16","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/1078-0432.CCR-12-1584","article-title":"Cabazitaxel: more than a new taxane for metastatic castrateresistant prostate cancer?","volume":"18","author":"Mita","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100422_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000007104","article-title":"Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line","volume":"44","author":"Fallo","year":"1998","journal-title":"Chemotherapy"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100422_bib18","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100422_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100422_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jcem-73-1-18","article-title":"Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1\/P-glycoprotein) which is also expressed by adrenocortical carcinomas","volume":"73","author":"Bates","year":"1991","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100422_bib21","first-page":"133","article-title":"Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells","volume":"14","author":"Villa","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1016\/j.esmoop.2022.100422_bib22","first-page":"117","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100422_bib23","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","article-title":"Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors","volume":"19","author":"Vrignaud","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100422_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100422_bib25","doi-asserted-by":"crossref","first-page":"110585","DOI":"10.1016\/j.mce.2019.110585","article-title":"In\u00a0vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures","volume":"498","author":"Fragni","year":"2019","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100422_bib26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study\u00a0of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100422_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","article-title":"Adrenocortical carcinoma. Endocrine Tumor Board of Gustave Roussy","volume":"44","author":"Baudin","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.esmoop.2022.100422_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100422_bib29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/cancers12061395","article-title":"Adrenocortical carcinoma and CT assessment of therapy response: the value of combining multiple criteria","volume":"12","author":"Ambrosini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2022.100422_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpba.2011.10.010","article-title":"Quantification of cabazitaxel in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry: a practical solution for non-specific binding","volume":"59","author":"de Bruijn","year":"2012","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.esmoop.2022.100422_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100422_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-19-0026","article-title":"Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study","volume":"180","author":"Berruti","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100422_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/iju5.12214","article-title":"Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second-line chemotherapy","volume":"3","author":"Yamamoto","year":"2020","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.esmoop.2022.100422_bib34","doi-asserted-by":"crossref","first-page":"674039","DOI":"10.3389\/fendo.2021.674039","article-title":"Case report: exceptional response to second line temozolomide therapy in a patient with metastatic adrenocortical carcinoma","volume":"12","author":"Cosentini","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100422_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/ERC-21-0040","article-title":"Targeted genomic analysis of 364 adrenocortical carcinomas","volume":"28","author":"Pozdeyev","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100422_bib36","doi-asserted-by":"crossref","first-page":"L13","DOI":"10.1530\/ERC-17-0467","article-title":"Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma","volume":"25","author":"Garinet","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.esmoop.2022.100422_bib37","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","article-title":"We should desist using RECIST, at least in GIST","volume":"25","author":"Benjamin","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100422_bib38","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-10-1708","article-title":"Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib","volume":"17","author":"Faivre","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100422_bib39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100422_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100422_bib41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-012-2058-9","article-title":"Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors","volume":"71","author":"Ferron","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100422_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00280-014-2394-z","article-title":"Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer","volume":"73","author":"Mukai","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100422_bib43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00280-016-3175-7","article-title":"A\u00a0phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function","volume":"78","author":"Azaro","year":"2016","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:03Z","timestamp":1761855963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000436"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100422","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100422"}}